You are here: Industry Insights > PD-1

News List

Made-in-China New Drugs: The Game and Breakthrough in the Over - 4 - Billion Market Lezhi
September 05, 2025
Profiles 16 China-made blockbuster drugs exceeding ¥1B sales, highlighting intense PD-1 competition, EGFR tech innovation, and bispecific antibody/non-oncology surge.
Made-in-China New Drugs: Breaking Through the RMB 4-Billion Battlefield lezhi
September 05, 2025
In 2024, the "Billion-Yuan Club" of made-in-China first-in-class new drugs expanded to 16 members.
Has the Booming PD-1 Inhibitor Reached its Limit? Krebs Qin
October 18, 2024
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
Next Stop for PD-1? MNC for Subcutaneous Preparation Takes the Lead in Competition, Leading to A More Fierce Domestic Conpetition, but Differentiation is not easy Spur 203/PharmaSources
December 14, 2023
The competition for the subcutaneous formulation of PD-1/PD-L1 inhibitors has been spreading globally for a long time, with Roche and Bristol Myers Squibb currently leading the pack.
How is the progress of China’s domestically produced PD-(L)1 “going global”? Yefenghong/PharmaSources
November 23, 2023
Recently, Coherus BioSciences announced that the FDA has approved the launch of PD-1 antibody toripalimab (marketed jointly by Junshi Biosciences and Coherus) for use in combination with gemcitabine/cisplatin as a first-line treatment for advanced recurre
FDA's Approval was Postponed Again, Chinese Innovative Pharmaceutical Companies has Extended Their Businesses to the Middle East and North Africa PharmaSources
April 27, 2023
The export of domestic PD-1 is much more difficult than expected.The Middle East and North Africa has become a new choice for the export of domestic innovative pharmaceutical companies in the past two years.
Global ICIs Market Exceeds USD 30 Billion in 2021, with its Number and Indications Approved Entering an Outbreak Period Yi
April 11, 2022
Lately, Opdualag, a fixed-dose compound preparation of BMS consisting of LAG-3 inhibitor relatlimab and PD-1 monoclonal antibody nivolumab, was approved by FDA for the treatment of adults and pediatric patients aged 12 years and older with unresectable or
In 2021, the sales volume of Innovent's PD-1 exceeded RMB 3 billion PharmaSources/Caicai
February 21, 2022
Chinese PD-1 also sells well. According to the quarterly sales data of Innovent's sintilimab (trade name: Tyvyt), its sales volume was about RMB 3.1 billion in 2021 (nominal sales revenue).
Penpulimab, the Fifth Chinese PD-1 Monoclonal Antibody, was approved for Marketing PharmaSources/Yefenghong
August 25, 2021
On August 5, penpulimab (AK105) developed by Akeso, Inc. was approved for marketing, which is used to treat patients with relapsed or refractory classic Hodgkin's lymphoma (r/r cHL) after second-line systemic chemotherapy.
Junshi’s Anti-PD-1 Drug Achieved Sales of RMB1.3 Billion in 2020 PharmaSources/Caicai
March 12, 2021
Junshi Biosciences has recently announced its 2020 annual performance preview, according to which, it achieved operating income of RMB1.595 billion, up 105.77% year on year, mainly thanks to the sales revenue growth of its anti-PD-1 drug.

Previous page 1 2 3 4 5 Next page